Guilford Street Laboratories
Guilford Street Laboratories (GSL), a UCL spin-out, is a contract research organization (CRO) specializing in highly precise and sensitive biomarker assays powered by machine learning-driven mass spectrometry. They offer services in proteomics, targeted lipid panels, and metabolite assays, catering to research objectives in early disease diagnosis, drug discovery, clinical trials, and personalized medicine. Their proprietary biomarker panels analyze protein, lipid, and metabolite markers. GSL's ImmunoTADA platform is a mass spectrometry-based system for quantifying antibody responses to therapies, aiming to revolutionize diagnostics for rare, cardiac, and neurodegenerative diseases. They have received an Arm's-Length Medical Grant from Chiesi Limited to advance their ImmunoTADA platform into clinical settings.
Guilford Street Laboratories
Guilford Street Laboratories (GSL), a UCL spin-out, is a contract research organization (CRO) specializing in highly precise and sensitive biomarker assays powered by machine learning-driven mass spectrometry. They offer services in proteomics, targeted lipid panels, and metabolite assays, catering to research objectives in early disease diagnosis, drug discovery, clinical trials, and personalized medicine. Their proprietary biomarker panels analyze protein, lipid, and metabolite markers. GSL's ImmunoTADA platform is a mass spectrometry-based system for quantifying antibody responses to therapies, aiming to revolutionize diagnostics for rare, cardiac, and neurodegenerative diseases. They have received an Arm's-Length Medical Grant from Chiesi Limited to advance their ImmunoTADA platform into clinical settings.
TL;DR
Founded: 2023 (UCL spin-out)
Focus: ML-driven mass spectrometry biomarker assays (proteins, lipids, metabolites)
Location: 30 Guilford St, London
Recent funding: Pre-seed announced 2024-05-17 led by GS Verde Group
Platform: ImmunoTADA — mass spectrometry-based antibody response quantification
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Biomarker measurement for diagnostics, clinical trials, drug discovery, and precision medicine.
Founded
2023
Industry
Biotechnology Research
Tech Stack
Funding Track Record
Pre-seed round announced May 17, 2024; GS Verde Group listed as lead/sole investor.
Investor Signal
“GS Verde Group led the pre-seed round announced May 17, 2024”